Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) — Net Asset Quality Index
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a Net Asset Quality Index of 94.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.02 Billion minus total liabilities of CN¥347.84 Million yields net assets of CN¥5.67 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See operational self-sufficiency of Wuhan Easy Diagnosis Biomedicine Co Ltd to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Net Asset Quality Index Over Time (2011–2025)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 94.2%, representing net assets of CN¥5.67 Billion against total assets of CN¥6.02 Billion CNY. Explore Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) cash conversion ratio to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Wuhan Easy Diagnosis Biomedicine Co Ltd market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.6% | CN¥5.66 Billion | CN¥5.98 Billion | CN¥324.56 Million | ▲ +3.3 pp |
| 2024 | 91.3% | CN¥6.02 Billion | CN¥6.59 Billion | CN¥574.40 Million | ▲ +6.1 pp |
| 2023 | 85.2% | CN¥6.29 Billion | CN¥7.39 Billion | CN¥1.09 Billion | ▲ +11.5 pp |
| 2022 | 73.7% | CN¥6.77 Billion | CN¥9.19 Billion | CN¥2.42 Billion | ▼ -9.7 pp |
| 2021 | 83.4% | CN¥2.85 Billion | CN¥3.42 Billion | CN¥567.02 Million | ▲ +5.3 pp |
| 2020 | 78.1% | CN¥1.11 Billion | CN¥1.43 Billion | CN¥311.77 Million | ▼ -18.3 pp |
| 2019 | 96.4% | CN¥615.62 Million | CN¥638.42 Million | CN¥22.80 Million | ▲ +0.4 pp |
| 2018 | 96.0% | CN¥592.59 Million | CN¥617.15 Million | CN¥24.55 Million | ▲ +1.3 pp |
| 2017 | 94.7% | CN¥242.93 Million | CN¥256.54 Million | CN¥13.60 Million | ▲ +5.9 pp |
| 2016 | 88.8% | CN¥175.08 Million | CN¥197.15 Million | CN¥22.07 Million | ▲ +2.7 pp |
| 2015 | 86.1% | CN¥115.39 Million | CN¥133.96 Million | CN¥18.57 Million | ▲ +4.9 pp |
| 2014 | 81.3% | CN¥49.59 Million | CN¥61.01 Million | CN¥11.42 Million | ▲ +24.1 pp |
| 2013 | 57.1% | CN¥13.60 Million | CN¥23.79 Million | CN¥10.19 Million | ▲ +26.6 pp |
| 2012 | 30.6% | CN¥1.42 Million | CN¥4.66 Million | CN¥3.23 Million | ▲ +29.5 pp |
| 2011 | 1.1% | CN¥21.45K | CN¥1.96 Million | CN¥1.94 Million | — |